ナミキ商事株式会社 医薬品及び創薬化学品の専門商社

医薬品及び創薬化学品の専門商社

検索検索

バイオ製品Bio Products

タンパク質、抗体、アッセイキット

タンパク質カタログ

輸入に関する法規制チェックは、御見積のご依頼をいただいた際に行います。
法規制によっては、定価として記載の価格に追加の費用が発生する場合や供給出来ない場合がございますので、あらかじめご了承ください。

サプライヤー
TargteMol
カタログNo.
TMPY-00776
製品名称
DLL4 Protein, Human, Recombinant (hFc)
タンパク質名
DLL4
Species
Human
HOST
HEK293 Cells
50μg: -
お問い合わせ

Overview

Synonyms δ-like 4 (Drosophila), Delta-like 4, hdelta2, delta-like 4 (Drosophila), hδ2, δ-like 4
Characteristics 1. Measured by its binding ability in a functional ELISA. Immobilized Mouse NOTCH1-His at 2 μg/ml (100 μl/well) can bind human DLL4-hFc , the EC50 of human DLL4-hFc is 15-90 ng/mL.
2. Measured by the ability of the immobilized protein to enhance BMP2-induced alkaline phosphatase activity in C3H10T1/2 mouse embryonic fibroblast cells. The ED50 for this effect is typically 1-8 ?g/mL in the presence of 500 ng/mL recombinant human BMP2.
Endotoxin Level < 1.0 EU/μg of the protein as determined by the LAL method.
Purity 95.80%
Description DLL4 Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 81 kDa and the accession number is Q9NR61.
Reference Martinez JC,et al.(2009) Nuclear and membrane expression of the angiogenesis regulator delta-like ligand 4 (DLL4) in normal and malignant human tissues. Histopathology. 54(5): 598-606.,Li JL,et al.(2010) Targeting DLL4 in tumors shows preclinical activity but potentially significant toxicity. Future Oncol. 6(7): 1099-103.,Yan M,et al.(2007) Delta-like 4/Notch signaling and its therapeutic implications. Clin Cancer Res. 13(24): 7243-6.,Sainson RC,et al.(2007) Anti-Dll4 therapy: can we block tumour growth by increasing angiogenesis? Trends Mol Med. 13(9): 389-95.
URL https://www.targetmol.com/recombinant-protein/dll4_protein_human_recombinant_ecd_hfc_tag_hplc_verified

お問い合わせリスト(-)

お問い合わせフォーム